论文部分内容阅读
Purpose. To compare the efficacy and safety of brimonidine 0.2% vs unoprostone 0.15% , both added to timolol maleate 0.5% each given twice daily. Methods. In this prospective, multi-centred, double-masked, crossover comparison, patients were randomized to one treatment group for a 6- week treatment period, and then crossed over to the opposite treatment. Measurements were performed at 0800, 1000, 1600, 1800, and 2000 h at baseline and at the end of each treatment period. Results. In all,33 patients entered this trial and 29 completed. The baseline trough intraocular pressure (IOP) was 23.3± 2.4 and the diurnal curve IOP was 22.0± 1.3mmHg. For the brimonidine and timolol maleate treatment group, the trough IOP was 21.6± 3.3 and the diurnal curve IOPwas 19.8± 2.1mmHg,while the timolol and unoprostone treatment showed a trough IOP of 20.9± 3.8 and a diurnal curve IOP of 19.3± 2.4 mmHg. There was no significant difference between treatment groups at any time point for the diurnal curve,or in the reduction from baseline (P >0.05). Both treatments failed to statistically reduce the IOP from baseline at 1800h. There was no difference between treatment groups regarding ocular and systemic unsolicited adverse events, but patients admitted to more dryness (P=0.02) and burning upon instillation (P< 0.0001) with unoprostone by survey. Conclusion. Brimonidine 0.2% or unoprostone 0.15% added to timolol maleate 0.5% provide similar efficacy and safety throughout the daytime diurnal curve.
Purpose. To compare the efficacy and safety of brimonidine 0.2% vs unoprostone 0.15%, both added to timolol maleate 0.5% each given twice daily. Methods. In this prospective, multi-centred, double-masked, crossover comparison, patients were randomized to one treatment group for a 6-week treatment period, and then crossed over to the opposite treatment. Measurements were performed at 0800, 1000, 1600, 1800, and 2000 h at baseline and at the end of each treatment period. , 33 patients entered this trial and 29 completed. The baseline trough intraocular pressure (IOP) was 23.3 ± 2.4 and the diurnal curve IOP was 22.0 ± 1.3 mmHg. For the brimonidine and timolol maleate treatment group, the trough IOP was 21.6 ± 3.3 and the diurnal curve IOPwas 19.8 ± 2.1 mmHg, while the timolol and unoprostone treatment showed a trough IOP of 20.9 ± 3.8 and a diurnal curve IOP of 19.3 ± 2.4 mmHg. There was no significant difference between treatment groups at any time point for the diurnal cur There was no difference between treatment groups regarding ocular and systemic unsolicited adverse events, but patients admitted to more dryness (P = 0.02) and burning upon instillation (P <0.0001) with unoprostone by survey. Conclusion. Brimonidine 0.2% or unoprostone 0.15% added to timolol maleate 0.5% provide similar efficacy and safety throughout the daytime diurnal curve.